AU2022334113A1 - Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions - Google Patents

Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions Download PDF

Info

Publication number
AU2022334113A1
AU2022334113A1 AU2022334113A AU2022334113A AU2022334113A1 AU 2022334113 A1 AU2022334113 A1 AU 2022334113A1 AU 2022334113 A AU2022334113 A AU 2022334113A AU 2022334113 A AU2022334113 A AU 2022334113A AU 2022334113 A1 AU2022334113 A1 AU 2022334113A1
Authority
AU
Australia
Prior art keywords
analogue
group
ttds
relaxin
lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022334113A
Other languages
English (en)
Inventor
Guido MAGNI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
River 2 Renal Corp
Original Assignee
River 2 Renal Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by River 2 Renal Corp filed Critical River 2 Renal Corp
Publication of AU2022334113A1 publication Critical patent/AU2022334113A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2022334113A 2021-08-23 2022-08-22 Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions Pending AU2022334113A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163236090P 2021-08-23 2021-08-23
US63/236,090 2021-08-23
US202263332994P 2022-04-20 2022-04-20
US63/332,994 2022-04-20
PCT/US2022/041095 WO2023028008A2 (en) 2021-08-23 2022-08-22 Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Publications (1)

Publication Number Publication Date
AU2022334113A1 true AU2022334113A1 (en) 2024-03-14

Family

ID=85322130

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022334113A Pending AU2022334113A1 (en) 2021-08-23 2022-08-22 Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Country Status (7)

Country Link
US (1) US20240400638A1 (https=)
EP (1) EP4392440A4 (https=)
JP (1) JP2024532403A (https=)
AU (1) AU2022334113A1 (https=)
CA (1) CA3229783A1 (https=)
MX (1) MX2024002335A (https=)
WO (1) WO2023028008A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52994A (fr) * 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20260035823A (ko) 2023-05-18 2026-03-13 테크토닉 오퍼레이팅 컴퍼니 인코포레이티드 렐락신-2 융합 단백질 유사체 및 이를 사용하는 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015528019A (ja) * 2012-07-31 2015-09-24 ノバルティス アーゲー セレラキシンを使用する炎症の処置
CN110637027B (zh) * 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
MA52994A (fr) * 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique

Also Published As

Publication number Publication date
EP4392440A4 (en) 2025-07-30
MX2024002335A (es) 2024-05-23
WO2023028008A2 (en) 2023-03-02
EP4392440A2 (en) 2024-07-03
US20240400638A1 (en) 2024-12-05
WO2023028008A3 (en) 2023-10-26
JP2024532403A (ja) 2024-09-05
CA3229783A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US12083164B2 (en) Amylin analogues
JP7295871B2 (ja) 修飾された脂質化リラキシンｂ鎖ペプチドおよびその治療的使用
TWI669309B (zh) 升糖素及ｇｌｐ－１共激動劑化合物
US20240400638A1 (en) Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
JP2020045362A (ja) グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
US10988523B2 (en) Modified lipidated Relaxin B chain peptides and their therapeutic use
JP2025106397A (ja) レナラーゼアゴニスト活性を有する安定なペプチド
WO2017149098A1 (en) Fusion respiratory syncytial virus inhibitors and use thereof
CN118510796A (zh) 用于治疗肾脏病症或疾患的松弛素和加压素类似物的组合
RU2804702C2 (ru) Модифицированные липидированные пептиды b-цепи релаксина и их терапевтическое применение
CN116650424A (zh) 新型多肽制剂及其治疗用途